Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States

K. Rajender Reddy, Caitlyn Ellerbe, Michael Schilsky, R. Todd Stravitz, Robert J. Fontana, Valerie Durkalski, William M. Lee

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Analyses of outcomes after acute liver failure (ALF) have typically included all ALF patients regardless of whether they were listed for liver transplantation (LT). We hypothesized that limiting analysis to listed patients might provide novel insights into factors associated with outcome, focusing attention on disease evolution after listing. Listed adult ALF patients enrolled in the US Acute Liver Failure Study Group registry between 2000 and 2013 were analyzed to determine baseline factors associated with 21-day outcomes after listing. We classified 617 patients (36% of overall ALF group) by 3-week outcome after study admission: 117 were spontaneous survivors (SSs; survival without LT), 108 died without LT, and 392 underwent LT. Only 22% of N-acetyl-p-aminophenol (APAP) ALF patients were listed; however, this group of 173 patients demonstrated greater illness severity: Higher coma grades and more patients requiring ventilator, vasopressor, or renal replacement therapy support. Only 62/173 (36%) of APAP patients received a graft versus 66% for drug-induced liver injury patients, 86% for autoimmune-related ALF, and 71% for hepatitis B-related ALF. APAP patients were more likely to die than non-APAP patients (24% versus 17%), and the median time to death was sooner (2 versus 4.5 days). Despite greater severity of illness, the listed APAP group still had a SS rate of 40% versus 11% for non-APAP causes (P <0.001). APAP outcomes evolve rapidly, mainly to SS or death. Patients with APAP ALF listed for LT had the highest death rate of any etiology, whereas more slowly evolving etiologies yielded higher LT rates and, consequently, fewer deaths. Decisions to list and transplant must be made early in all ALF patients, particularly in those with APAP ALF.

Original languageEnglish (US)
Pages (from-to)505-515
Number of pages11
JournalLiver Transplantation
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Acute Liver Failure
Liver Transplantation
Acetaminophen
Transplants
Chemical and Drug Induced Liver Injury
Renal Replacement Therapy
Mechanical Ventilators
Coma
Hepatitis B
Survivors
Registries

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. / Reddy, K. Rajender; Ellerbe, Caitlyn; Schilsky, Michael; Stravitz, R. Todd; Fontana, Robert J.; Durkalski, Valerie; Lee, William M.

In: Liver Transplantation, Vol. 22, No. 4, 01.04.2016, p. 505-515.

Research output: Contribution to journalArticle

Reddy, K. Rajender ; Ellerbe, Caitlyn ; Schilsky, Michael ; Stravitz, R. Todd ; Fontana, Robert J. ; Durkalski, Valerie ; Lee, William M. / Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. In: Liver Transplantation. 2016 ; Vol. 22, No. 4. pp. 505-515.
@article{4830cf94a92c4d56a0333206c45f7375,
title = "Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States",
abstract = "Analyses of outcomes after acute liver failure (ALF) have typically included all ALF patients regardless of whether they were listed for liver transplantation (LT). We hypothesized that limiting analysis to listed patients might provide novel insights into factors associated with outcome, focusing attention on disease evolution after listing. Listed adult ALF patients enrolled in the US Acute Liver Failure Study Group registry between 2000 and 2013 were analyzed to determine baseline factors associated with 21-day outcomes after listing. We classified 617 patients (36{\%} of overall ALF group) by 3-week outcome after study admission: 117 were spontaneous survivors (SSs; survival without LT), 108 died without LT, and 392 underwent LT. Only 22{\%} of N-acetyl-p-aminophenol (APAP) ALF patients were listed; however, this group of 173 patients demonstrated greater illness severity: Higher coma grades and more patients requiring ventilator, vasopressor, or renal replacement therapy support. Only 62/173 (36{\%}) of APAP patients received a graft versus 66{\%} for drug-induced liver injury patients, 86{\%} for autoimmune-related ALF, and 71{\%} for hepatitis B-related ALF. APAP patients were more likely to die than non-APAP patients (24{\%} versus 17{\%}), and the median time to death was sooner (2 versus 4.5 days). Despite greater severity of illness, the listed APAP group still had a SS rate of 40{\%} versus 11{\%} for non-APAP causes (P <0.001). APAP outcomes evolve rapidly, mainly to SS or death. Patients with APAP ALF listed for LT had the highest death rate of any etiology, whereas more slowly evolving etiologies yielded higher LT rates and, consequently, fewer deaths. Decisions to list and transplant must be made early in all ALF patients, particularly in those with APAP ALF.",
author = "Reddy, {K. Rajender} and Caitlyn Ellerbe and Michael Schilsky and Stravitz, {R. Todd} and Fontana, {Robert J.} and Valerie Durkalski and Lee, {William M.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/lt.24347",
language = "English (US)",
volume = "22",
pages = "505--515",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States

AU - Reddy, K. Rajender

AU - Ellerbe, Caitlyn

AU - Schilsky, Michael

AU - Stravitz, R. Todd

AU - Fontana, Robert J.

AU - Durkalski, Valerie

AU - Lee, William M.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Analyses of outcomes after acute liver failure (ALF) have typically included all ALF patients regardless of whether they were listed for liver transplantation (LT). We hypothesized that limiting analysis to listed patients might provide novel insights into factors associated with outcome, focusing attention on disease evolution after listing. Listed adult ALF patients enrolled in the US Acute Liver Failure Study Group registry between 2000 and 2013 were analyzed to determine baseline factors associated with 21-day outcomes after listing. We classified 617 patients (36% of overall ALF group) by 3-week outcome after study admission: 117 were spontaneous survivors (SSs; survival without LT), 108 died without LT, and 392 underwent LT. Only 22% of N-acetyl-p-aminophenol (APAP) ALF patients were listed; however, this group of 173 patients demonstrated greater illness severity: Higher coma grades and more patients requiring ventilator, vasopressor, or renal replacement therapy support. Only 62/173 (36%) of APAP patients received a graft versus 66% for drug-induced liver injury patients, 86% for autoimmune-related ALF, and 71% for hepatitis B-related ALF. APAP patients were more likely to die than non-APAP patients (24% versus 17%), and the median time to death was sooner (2 versus 4.5 days). Despite greater severity of illness, the listed APAP group still had a SS rate of 40% versus 11% for non-APAP causes (P <0.001). APAP outcomes evolve rapidly, mainly to SS or death. Patients with APAP ALF listed for LT had the highest death rate of any etiology, whereas more slowly evolving etiologies yielded higher LT rates and, consequently, fewer deaths. Decisions to list and transplant must be made early in all ALF patients, particularly in those with APAP ALF.

AB - Analyses of outcomes after acute liver failure (ALF) have typically included all ALF patients regardless of whether they were listed for liver transplantation (LT). We hypothesized that limiting analysis to listed patients might provide novel insights into factors associated with outcome, focusing attention on disease evolution after listing. Listed adult ALF patients enrolled in the US Acute Liver Failure Study Group registry between 2000 and 2013 were analyzed to determine baseline factors associated with 21-day outcomes after listing. We classified 617 patients (36% of overall ALF group) by 3-week outcome after study admission: 117 were spontaneous survivors (SSs; survival without LT), 108 died without LT, and 392 underwent LT. Only 22% of N-acetyl-p-aminophenol (APAP) ALF patients were listed; however, this group of 173 patients demonstrated greater illness severity: Higher coma grades and more patients requiring ventilator, vasopressor, or renal replacement therapy support. Only 62/173 (36%) of APAP patients received a graft versus 66% for drug-induced liver injury patients, 86% for autoimmune-related ALF, and 71% for hepatitis B-related ALF. APAP patients were more likely to die than non-APAP patients (24% versus 17%), and the median time to death was sooner (2 versus 4.5 days). Despite greater severity of illness, the listed APAP group still had a SS rate of 40% versus 11% for non-APAP causes (P <0.001). APAP outcomes evolve rapidly, mainly to SS or death. Patients with APAP ALF listed for LT had the highest death rate of any etiology, whereas more slowly evolving etiologies yielded higher LT rates and, consequently, fewer deaths. Decisions to list and transplant must be made early in all ALF patients, particularly in those with APAP ALF.

UR - http://www.scopus.com/inward/record.url?scp=84961710704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961710704&partnerID=8YFLogxK

U2 - 10.1002/lt.24347

DO - 10.1002/lt.24347

M3 - Article

C2 - 26421889

AN - SCOPUS:84961710704

VL - 22

SP - 505

EP - 515

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 4

ER -